Analytica raising $4m for PeriCoach launch
10 October, 2014 by Dylan Bushell-EmblingAnalytica (ASX:ALT) has secured a CE Mark for its PeriCoach device and has launched an up to $4m capital raising to help fund marketing ahead of its formal launch in Australia.
Annual Report 2014: AusBiotech "facilitating global development"
09 October, 2014The AusBiotech Annual Report 2014 is now available, detailing how AusBiotech is delivering on its plan to facilitate global development of the Australian life sciences industry.
BVA's bionic eye implant shown to be safe
09 October, 2014 by Dylan Bushell-EmblingBionic Vision Australia's (BVA) prototype 24-channel percutaneous connector implant was found to be safe during its first clinical trial in retinosis pigmentosa.
Antara Lifesciences raises $7m in IPO
07 October, 2014 by Dylan Bushell-EmblingAntara Lifesciences (ASX:ANR) will use the proceeds from its recent IPO to help commercialise non-antibiotic diarrhoea treatment Detach in livestock animals and develop a version for humans.
Public forum on biotech's role in treatment of dementias and Alzheimer's
07 October, 2014With more than 332,000 Australians currently living with dementia and this figure expected to increase to 400,000 in less than a decade, AusBiotech will hold a free public forum with Australia's leading experts discussing what the future holds for the treatment and prevention of dementias and Alzheimer's and the supports available for those affected.
Phosphagenics beats market leader in acne trial
07 October, 2014 by Dylan Bushell-EmblingPhosphagenics' TPM-Tretinoin drug candidate outperformed the market leader during a phase II trial, with the results suggesting that TPM itself has inherent anti-acne qualities.
VivaGel condoms to go on sale this month
03 October, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) and partner Ansell (ASX:ANN) have registered their VivaGel coated condom on the ARTG and plan to launch the product in Australia this month.
MCRI, Curve Tomorrow win top award in Silicon Valley
02 October, 2014 by Dylan Bushell-EmblingMurdoch Childrens Research Institute and Curve Tomorrow have won first place in the Launch! session of the Annual Fall Health 2.0 conference in California.
New report on the uptake of assistive health technologies in Australia
02 October, 2014Australia needs to actively drive the uptake of assistive healthcare technologies to allow people to stay at home longer and live more independently, according to a new Australian Council of Learned Academies (ACOLA) report.
Merck buying Sigma-Aldrich for $19.6bn
01 October, 2014 by Dylan Bushell-EmblingGermany's Merck has arranged to acquire chemical and biochemical supplier Sigma-Aldrich in a deal worth US$17bn.
Queensland Government responds in support of review of Gene Technology Act
30 September, 2014The Queensland Government's response to the recommendations of the review of the operation of the Gene Technology Act 2001 (Qld) has been released. The government said its response to the review recommendations was prepared in consultation with relevant departments "who generally support the findings of the review".
Global Kinetics' PKG being trialled in the UK
30 September, 2014 by Dylan Bushell-EmblingGlobal Kinetics is collaborating with research and support charity Parkinson's UK for a 12-month pilot trial of the company's Parkinson's KinetiGraph symptom monitoring devices.
Antisense raising $2.5m for trials, partnering plans
26 September, 2014Antisense Therapeutics (ASX:ANP) is raising up to $2.5m to fund trials of its drug candidates in acromegaly and relapse remitting multiple sclerosis.
Support the Australian Innovation & Manufacturing Incentive
26 September, 2014AusBiotech is advocating for the Australian Innovation and Manufacturing (AIM) Incentive as an amendment to the current Australian corporate tax regime and seeks case study examples of Australian businesses that would benefit from such an amendment.
INV102 being well tolerated in asthma trial: Invion
24 September, 2014 by Dylan Bushell-EmblingInvion (ASX:IVX) may be on the way to reversing the contraindication for nadolol in asthma, if interim results from a phase II trial of INV102 are an indication.
